Article (Scientific journals)
Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG
Van der Werff Ten Bosch, J; Suciu, S; Thyss, A et al.
2005In Leukemia, 19 (5), p. 721-6
Peer Reviewed verified by ORBi
 

Files


Full Text
26 Van der Werff.pdf
Publisher postprint (120.97 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
6-MP; childhood; ALL; NHL; randomized trial
Abstract :
[en] Between November 1990 and November 1996, EORTC Children Leukemia Group conducted a randomized trial in de novo acute lymphoblastic leukemia and lymphoblastic non-Hodgkin’s lymphoma patients using a Berlin–Frankfurt–Munster protocol to evaluate the monthly addition of intravenous 6-mercaptopurine (i.v. 6-MP) (1 g/m2) to conventional continuation therapy comprising per oral MTX weekly and 6-MP daily. Only during the first 18 months of the randomization period, 6-MP p.o. was interrupted for 1 week after each i.v. 6-MP. A total of 877 patients was randomized to either no i.v. 6-MP (Arm A) or additional i.v. 6-MP (Arm B). A total of 217 relapses (91 in Group A vs 128 in Group B) and 13 deaths in CR (5 vs 8) were reported; a total of 134 patients (55 vs 79) died. The median follow-up was 7.6 years. At 8 years, the disease-free survival rate was lower (P¼0.005) in Arm B (69.1% (s.e.¼2.2%)) than in Arm A (77.9% (s.e.¼2.0%)), and the hazard ratio was 1.45 (95% CI 1.12–1.89). In conclusion, as delivered in this study, i.v. 6-MP was detrimental to event-free survival.
Disciplines :
Hematology
Pediatrics
Oncology
Author, co-author :
Van der Werff Ten Bosch, J
Suciu, S
Thyss, A
Bertrand, Y
Norton, L
Mazingue, F
Uyttebroeck, A
Robert, A
Boutard, P
Ferster, A
Plouvier, E
Maes, P
Munzer, M
Plantaz, D
DRESSE, Marie-Françoise ;  Centre Hospitalier Universitaire de Liège - CHU > Service de pédiatrie (CHR)
Philippet, P
Sirvent, N
Waterkeyn, C
Vilmer, E
Philippe, N
Otten, J
More authors (11 more) Less
Language :
English
Title :
Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG
Publication date :
May 2005
Journal title :
Leukemia
ISSN :
0887-6924
eISSN :
1476-5551
Publisher :
Nature Publishing Group, London, United Kingdom
Volume :
19
Issue :
5
Pages :
721-6
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 29 May 2016

Statistics


Number of views
80 (2 by ULiège)
Number of downloads
138 (0 by ULiège)

Scopus citations®
 
25
Scopus citations®
without self-citations
14
OpenCitations
 
25

Bibliography


Similar publications



Contact ORBi